dr. mesa on the differences between fedratinib and ruxolitinib in myelofibrosis
Published 4 years ago • 36 plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
1:00
dr. mesa on the utility of ruxolitinib versus fedratinib in myelofibrosis
-
1:42
dr. mesa on ruxolitinib vs fedratinib in myelofibrosis treatment
-
1:11
dr. mesa on the utility of fedratinib for patients with myelofibrosis who progress on ruxolitinib
-
1:24
dr. mesa on current data with ruxolitinib and fedratinib in myelofibrosis
-
1:16
dr. mesa on the fda approval of fedratinib in myelofibrosis
-
1:29
dr. mesa on the fda approval of fedratinib in myelofibrosis
-
2:13
dr. mesa on the efficacy of fedratinib in patients with myelofibrosis and low platelet counts
-
2:03
dr. mesa on jakarta-2 reanalysis for myelofibrosis
-
0:57
dr. mesa on challenges in myelofibrosis treatment
-
7:43
the role of fedratinib in myelofibrosis
-
1:40
fedratinib compared to ruxolitinib in the frontline setting for treatment of myelofibrosis
-
0:50
dr. snyder on how ruxolitinib and fedratinib may pave the way to transplant in myelofibrosis
-
1:14
dr. mesa on the safety profiles of jak inhibitors in myelofibrosis
-
0:59
dr. michaelis on fedratinib in myelofibrosis treatment
-
3:52
comparison of ruxolitinib vs fedratinib and practical implications
-
1:14
dr. mesa on the emergence of jak inhibitors in myelofibrosis
-
1:27
dr. kuykendall on choosing ruxolitinib or fedratinib in myelofibrosis
-
2:34
dr. mesa on ruxolitinib in myelofibrosis
-
1:42
dr. mesa on jak inhibitors in the pipeline for myelofibrosis